HLA-DRB1 and DQB1 Alleles, Haplotypes and Genotypes in Emirati Patients with Type 1 Diabetes Underscores the Benefits of Evaluating Understudied Populations

Zain Al Yafei1, Steven J. Mack2, Marion Alvares1, Bassam R. Ali3, Bachar Afandi4, Salem A. Beshyah4, Charu Sharma6, Wael Osman7, Rajaa Mirghani8, Amre Nasr9, Sareaa Al Remithi1, Jamal Al Jubeh1, Wasim Y. Almawi10, Juma AlKaabi4,6 and Gehad ElGhazali1,6*

1Sheikh Khalifa Medical City, Purehealth, Abu Dhabi, United Arab Emirates, 2Department of Pediatrics, University of California, San Francisco, San Francisco, CA, United States, 3Department of Genetics and Genomics, College of Medicine and Health Sciences, United Arab Emirates University, Al Ain, United Arab Emirates, 4Department of Internal Medicine, Tawam Hospital, Al Ain, United Arab Emirates, 5Department of Medicine, Dubai Medical College, Dubai, United Arab Emirates, 6Department of Internal Medicine, United Arab Emirates University, Al Ain, United Arab Emirates, 7College of Arts and Sciences, Khalifa University, Abu Dhabi, United Arab Emirates, 8Higher College of Technology, Abu Dhabi, United Arab Emirates, 9Department of Basic Medical Sciences, College of Medicine, King Saud Bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia, 10Department of Biomedical Sciences, Nazarbayev University School of Medicine, Astana, Kazakhstan

Background: HLA class II (DR and DQ) alleles and antigens have historically shown strong genetic predisposition to type 1 diabetes (T1D). This study evaluated the association of DRB1 and DQB1 alleles, genotypes, and haplotypes with T1D in United Arab Emirates.

Materials and Methods: Study subjects comprised 149 patients with T1D, and 147 normoglycemic control subjects. Cases and controls were Emiratis and were HLA-DRB1 and -DQB1 genotyped using sequence-based typing. Statistical analysis was performed using Bridging Immunogenomic Data-Analysis Workflow Gaps R package.

Results: In total, 15 DRB1 and 9 DQB1 alleles were identified in the study subjects, of which the association of DRB1*03:01, DRB1*04:02, DRB1*11:01, DRB1*16:02, and DQB1*02:01, DQB1*03:02, DQB1*03:01, and DQB1*06:01 with altered risk of T1D persisted after correcting for multiple comparisons. Two-locus haplotype analysis identified DRB1*03:01−DQB1*02:01 [0.44 vs. 0.18, OR (95% CI) = 3.44 (2.33–5.1), Pc = 3.48 x 10^{-10}], DRB1*04:02−DQB1*03:02 [0.077 vs. 0.014, OR = 6.06 (2.03–24.37), Pc = 2.3 x 10^{-3}] and DRB1*04:05−DQB1*03:02 [0.060 vs. 0.010, OR = 6.24 (1.79–33.34), Pc = 0.011] as positively associated, and DRB1*16:02−DQB1*05:02 [0.024 vs. 0.075, OR = 0.3 (0.11–0.74), Pc = 0.041] as negatively associated with T1D, after applying Bonferroni correction. Furthermore, the highest T1D risk was observed for DR3/DR4 [0.104 vs. 0.006, OR = 25.03 (8.23–97.2), Pc = 2.6 x 10^{-13}], followed by DR3/DR3 [0.094 vs. 0.010, OR = 8.72 (3.17–25.32), Pc = 3.18 x 10^{-8}] diplotypes.

Conclusion: While DRB1 and DQB1 alleles and haplotypes associated with T1D in Emiratis showed similarities to Caucasian and non-Caucasian populations, several alleles
and haplotypes associated with T1D in European, African, and Asian populations, were not observed. This underscores the contribution of ethnic diversity and possible diverse associations between DRB1 and DQB1 and T1D across different populations.

Keywords: type 1 diabetes, HLA, haplotypes, Emiratis, ethnicity

INTRODUCTION

Type 1 diabetes (T1D) is a complex autoimmune disorder characterized by insulin deficiency resulting from autoimmune destruction of insulin-secreting pancreatic β-cells in genetically predisposed individuals (Eisenbarth, 2010).

The International Diabetes Federation estimates that more than 1.1 million individuals below the age of 20 years are diagnosed with T1D worldwide (International Diabetes Federation, 2019). In this regard, it was reported that the incidence of T1D in children (15 years or younger) varies greatly among different ethnic and racial groups, highlighted by high to intermediate incidence among Europeans e.g., 5.2/100,000 per year in Finland (International Diabetes Federation, 2019; Knip, 2021), and the low incidence among Asians e.g., 1.8/100,000 per year in China (Gong et al., 2015; International Diabetes Federation, 2019). Among Arab populations of the Middle East, it was estimated that there are about 60,000 children with T1D under the age 15 years (Zayed, 2016). Of these, Kuwait and Saudi Arabia rank among the top ten countries worldwide in T1D prevalence, with rates of 44.5/100,000 and 33.5/100,000, respectively (Majeed et al., 2014; Shaltout et al., 2017; International Diabetes Federation, 2019). No reliable data have yet been reported on the T1D incidence in the United Arab Emirates (UAE). While the reason underlying the differences in T1D prevalence rate according to ethnicity and geographical locations is not known (Patterson et al., 2014; IDF 2019), it was suggested that both environmental parameters and genetic influence the initiation of T1D development (Eisenbarth, 2010; Blanter et al., 2019; Xia et al., 2019).

More than 60 genetic loci were reported in the literature as associated with altered T1D susceptibility (Todd et al., 2007; Bergholdt et al., 2012; Xia et al., 2019), of which the Human Leukocyte Antigens (HLA) class II genes contributed to approximately one-half of T1D genetic risk (Noble et al., 1996; Pociot et al., 2010). Individual DRB1 and DQB1 alleles, or allelic combinations were associated with the altered risk of T1D, and both susceptible and protective DRB1, DQA1, and DQB1 alleles were reportedly implicated with T1D pathogenesis (Noble et al., 1996; Erlich et al., 2008). This was highlighted by the association of DRB1*03:01~DQB1*02:01 and DRB1*04:01~DQB1*03:02 haplotypes with increased susceptibility to T1D among Bahraini Arabs (Al-Jenaidi et al., 2005). As the frequencies of HLA alleles, haplotypes, and genotypes show considerable population and ethnic differences, population studies confirmed that the relationship of HLA with T1D also varies according to the geographical location and ethnic background (Al-Jenaidi et al., 2005; Ahmadov et al., 2018; Fawwad et al., 2019; Zabeen et al., 2019). Compared to numerous studies performed on European populations, limited numbers of studies have been conducted on populations in the Middle East-North Africa (MENA) region (Al-Jenaidi et al., 2005; Noble et al., 2013).

This is the first case-control study investigating the association of HLA with T1D in the Emirati population. The present-day UAE national population is characterized by high rates of consanguinity, endogamy, along with sizeable extended families, and tribal community nature (Zayed, 2016). These and other features further justify investigating the association of HLA-class II antigens in T1D among Emirati Arabs. In addition to screening individual alleles, we aimed to assess the prevalence of DRB1~DQB1 haplotype combination in search of specific susceptible and protective haplotypes.

MATERIALS AND METHODS

Study Population

The study subjects comprised 149 unrelated patients with T1D and 147 unrelated normoglycemic controls who were recruited from outpatient T1D clinics at Sheikh Khalifa Medical City (Abu Dhabi, UAE) and Tawam Hospital (Al-Ain, UAE). T1D was diagnosed based on clinical features and laboratory findings and on the 1985 World Health Organization (WHO) criteria (WHO Technical Report Series 727; World Health Organization, 1985) and the classification of diabetes mellitus document, WHO, Geneva; 2019 (World Health Organization, 1985; World Health Organisation, 2019). The inclusion criteria were patients who presented with acute symptoms of diabetes (e.g., polyuria, polydipsia and weight loss), had random blood glucose >200 mg/dl (11.1 mmol/L), C-peptide levels of <0.3 mmol/L, and hyperglycemia ≥5.0 mmol/L (90 mg/dl)

TABLE 1 | Clinical and demographic characteristics of the study population.

| Variable | Patients (149) | Control (147) |
|----------|---------------|---------------|
| Age      | 18.32 ± 7.45 years | 19.71 ± 6.93  |
| Gender   |               |               |
| Male     | 69 (46.2)     | 65 (44.2)     |
| Female   | 80 (53.8)     | 82 (55.8)     |
| Mode of presentation for TID |               |               |
| DKA      | 64 (42.9)     |               |
| Hyperglycemia | 68 (45.6) |               |
| Duration of diabetes | 10.51 ± 6.15 | 10.51 ± 6.15 |
| <5 years | 33 (22.1)     |               |
| 5–10 years | 42 (28.5)    |               |
| >10 years | 74 (49.7)     |               |
| HbA1c (%) | 8.8 ± 1.9     |               |
| Established autoimmune diseases | 23 (15.7) | None          |
| Celiac disease | 5 (3.5) | None          |
| Thyroid disease | 18 (12.1) | None          |
| Family History of T1D | 50 (33.6) | None          |
| Family history of autoimmune diseases | 62 (42) | None          |

Poceti et al., 2010). This was highlighted by the association of DRB1*03:01~DQB1*02:01 and DRB1*04:01~DQB1*03:02 haplotypes with increased susceptibility to T1D among Bahraini Arabs (Al-Jenaidi et al., 2005). As the frequencies of HLA alleles, haplotypes, and genotypes show considerable population and ethnic differences, population studies confirmed that the relationship of HLA with T1D also varies according to the geographical location and ethnic background (Al-Jenaidi et al., 2005; Ahmadov et al., 2018; Fawwad et al., 2019; Zabeen et al., 2019). Compared to numerous studies performed on European populations, limited numbers of studies have been conducted on populations in the Middle East-North Africa (MENA) region (Al-Jenaidi et al., 2005; Noble et al., 2013).
had required long term insulin therapy since the time of diagnosis. Exclusion criteria included monogenic diabetes recognized by autosomal dominant mode of inheritance, type 2 diabetes as manifested by obesity and signs of insulin resistance, diabetes diagnosed before the age of 12 months or chronic diseases (especially autoimmune diseases) and patients/guardians who were unable to provide consent to participate in the study. Control individuals consisted of university students and healthy children with normal fasting/random blood glucose levels, no family history of T1D or other autoimmune diseases and were matched for age and gender with patients with T1D. Healthy children (≤16 years) were enrolled during routine hospital visits for other complaints while medical students (adolescents/adults) were recruited from the Tawam teaching hospital (Al Ain, UAE). For each recruited patient with T1D, a control was matched for age and gender to the extend possible. The mean ± SD age were 18.32 ± 7.45 (range 6–26 years) and 19.71 ± 6.93 (6–24) of cases and controls, respectively. Patients with T1D and their controls were Emirati nationals with grandparents born in the United Arab Emirates. Table 1 presents basic clinical and demographic characteristics of the study population.

This study was performed following the guidelines of the Declaration of Helsinki (1993). The study protocol was approved by the Institutional Review Boards at SKMC (REC-25-10-2016 RS-445) and United Arab Emirates University (AAMDHREC 2016-4255 16-002), and informed consent was acquired from all study subjects or their guardians before performing the study.

Human Leukocyte Antigen Typing

All samples were analysed in our laboratory, which is a well-established clinical laboratory accredited by both the College of American Pathologists (CAP) and ISO15189. Total genomic DNA was extracted from EDTA-anticoagulated peripheral blood of study subjects using Qiagen DNA Mini kit on automated QIAcube, according to the manufacturer instructions (Qiagen, Hilden, Germany). DNA concentrations were determined using NanoDrop-2000 (Wilmington, DE, United States), and HLA-DRB1 and -DQB1 genotyping was performed by sequence-based typing (SBT), using GenDx AlleleSEQR kits (GenDx, https://www.gendx.com/, Netherland). Based on the method, exon 2 was sequenced for HLA-DRB1(AlleleSEQR HLA-DRB1, product code 08K63-03), and exon 2 and 3 were sequenced for HLA-DQB1 (AlleleSEQR HLA-DQBQ1, product code 08K64-03). All reagents necessary for primary amplification and sequencing were included in the HLA-DRB1 and –DQB1 AlleleSEQR SBT kits (GenDx, Netherland). Briefly, following the primary amplification using 9700 thermal cycler (Applied Biosystems, United States), the PCR products were purified by ExoSAP-IT and the PCR products were sequenced using BigDye Terminatory chemistry and the ABI-3130 genetic sequencer (Applied Biosystems, Foster City, CA). Finally, the sequence data were analysed using the GenDx SBTengine HLA typing software (http://www.gendx.com/product_line/sbtengine/), as described in the manufacturer’s protocol. Quality control measures consisted of randomly-choosing 10% of cases and control samples for retyping; concordance was 100%.

In addition, six samples from the CAP External Quality Control Proficiency testing program were used to ensure control for the genotyping procedures.

Statistical Analysis

The association of HLA-DRB1 and -DQB1 alleles and haplotypes with T1D was analysed using the Bridging Immunogenomic Data-Analysis Workflow Gaps (BIGDAWG) package (version 2.1) (Pappas et al., 2016), with 95% confidence intervals (CI), odds ratios (OR), and P-values (P) reported. BIGDAWG’s haplotype estimation function, which required the R “haplo.stats” package (version 1.7.7), was also used. Allele counts < 5 in study subjects were collapsed automatically through BIGDAWG into “binned” category (Pappas et al., 2016). The same analyses were performed at the haplotype level, which were estimated by the expectation-maximization (EM) approach (Dempster et al., 1977), and haplotypes with counts of three or fewer were binned. The corrected P values (Pc) for multiple comparisons were calculated using the Benferroni method. Analysis of Hardy-Weinberg equilibrium (HWE) deviations for specific haplotypes and individual loci was performed using PyPop (version 0.8.0), and Guo and Thompson’s exact method was used in identifying significant locus-level HWE deviations (Guo and Thompson, 1992; Lancaster et al., 2007). Individual haplotype deviations from HWE expectations were determined by Chen’s method (Guo and Thompson, 1992), at a significance of 0.05.

The pould ( phased or unphased LD) R package (version 0.10.4.9000) (https://cran.r-project.org/package=pould) (Osoegawa et al., 2019) was used to calculate D’, Wn, Wn/a,  and Wn/b/a global linkage disequilibrium (LD) values for DRB1–DQB1 haplotypes (Thomson and Single 2014), in the range of 0 (equilibrium) to 1 (linkage). In LD, D’ signifies the weighted average of normalized disequilibrium (Dn) values, and it is less sensitive to variation across haplotypes of polymorphic loci than the other measures. Moreover, Wn a indicates a correlation coefficient describing the association between alleles at two loci. The conditional asymmetric LD (ALD) measures, including Wn/b and Wn/a/b, extend the weighted measure for variation at one locus (a) conditioned on the variation at the second (b) (Single et al., 2016).

RESULTS

Deviation From HWE

There was no deviation from HWE at DRB1 and DQB1 loci among controls, and no HWE deviation for DRB1 locus in patients, however, the DQB1 locus indicated an overall deviation from HWE (p = 0.0006) in patients. No trend toward excess heterozygosity or homozygosity was detected in patients. This deviation was due to the presence of five rare DQB1 genotypes—DQB1*02:03+DQB1*03:04 (1 observed (obs); 0.0268 expected (exp); p = 0.0271), DQB1*03:03+DQB1*04:01 (1 obs; 0.0067 exp; p = 0.0073), DQB1*02:03+DQB1*06:03 (1 obs; 0.0403 exp; p = 0.0088), DQB1*06:03+DQB1*06:03 (1 obs 0.0015 exp; p = 0.0106), and DQB1*05:01+DQB1*06:09 (1 obs; 0.0469 exp; p = 0.0538).
Many of these alleles are observed less than five times in patients or controls (Supplementary Tables S1, S3).

**HLA-DRB1 and -DQB1 Allele Frequencies**

Significant DRB1 allelic differences were seen between T1D patients and control subjects, 10 of 31 alleles differing significantly ($P < 0.05$). When the Bonferroni correction was applied, differences were significant for only 4, which comprised DRB1*03:01 [0.44 vs. 0.187, OR (95% CI) = 3.46 (2.35–5.11), $P_c = 3.2 	imes 10^{-10}$] and DRB1*04:02 [0.081 vs. 0.014, OR = 6.35 (2.14–25.44), $P_c = 2.0 	imes 10^{-3}$], which were higher among patients, and DRB1*11:01 [0.003 vs. 0.044, OR = 0.07 (0–0.49), $P_c = 0.015$] and DRB1*16:02 [0.023 vs. 0.078, OR = 0.28 (0.1–0.7), $P_c = 0.030$], which were higher in control subjects (Table 2). Similarly, significant allelic differences were seen at the DQB1 locus, 5 of 9 alleles differing significantly after the Bonferroni correction. These comprised DQB1*02:01 [0.48 vs. 0.19, OR = 3.78 (2.58–5.57), $P_c = 3.04 	imes 10^{-13}$] and DQB1*03:02 [0.21 vs. 0.08, OR = 3.1 (1.82–5.40), $P_c = 5.84 	imes 10^{-4}$] which were higher among patients, and DQB1*03:01 [0.02 vs. 0.11, OR = 0.16 (0.05–0.40), $P_c = 5.64 	imes 10^{-5}$], DQB1*05:01 [0.05 vs. 0.11, OR = 0.40 (0.19–0.80), $P_c = 0.044$], and DQB1*06:01 [0.003 vs. 0.06, OR = 0.05 (0–0.33), $P_c = 5.84 	imes 10^{-4}$], which were higher among control subjects (Table 3).

**Distribution of DRB1-DQB1 Haplotypes**

In total, 95 distinct DRB1-DQB1 haplotypes were identified (Supplementary Table S2), of which 42 had counts of ≥2 in controls or patients, and thus were considered common. In total, four individual haplotypes showing a statistically significant association with T1D (Table 4). The full list of DRB1–DQB1 haplotypes that were binned due to low expected counts is given in Supplementary Table S4. Higher frequencies of DRB1*03:01–DQB1*02:01 [0.44 vs. 0.18, OR = 3.44 (2.33–5.10), $P_c = 3.48 	imes 10^{-15}$], DRB1*04:02–DQB1*03:02 [0.077 vs. 0.014, OR = 6.06 (2.03–24.37), $P_c = 2.3 	imes 10^{-3}$], and DRB1*04:05–DQB1*03:02 [0.06 vs. 0.01, OR = 6.24 (1.79–33.34), $P_c = 0.011$] haplotypes, and lower frequency

**Table 2** | Associations of DRB1 alleles with T1D in Emirati study subjects.

| Allele  | Patient$^a$ | Control$^a$ | OR (95%CI) | $p$-value | $P_{\text{corrected}}$ $^b$ |
|---------|-------------|-------------|------------|-----------|------------------|
| 01:01   | 4 (0.013)$^c$ | 7 (0.024)   | 0.56 (0.12–2.22) | 0.349 | NA |
| 01:02   | 5 (0.017)   | 8 (0.027)   | 0.61 (0.16–2.15) | 0.386 | NA |
| 03:01   | 132 (0.44)  | 55 (0.167)  | 3.46 (2.35–5.11) | $2.1 	imes 10^{-11}$ | $3.2 	imes 10^{-10}$ |
| 04:02   | 24 (0.081)  | 4 (0.014)   | 6.35 (2.14–25.44) | $1.3 	imes 10^{-4}$ | $2.0 	imes 10^{-3}$ |
| 04:03   | 6 (0.02)    | 15 (0.051)  | 0.98 (0.12–1.06) | 0.042 | 0.630 |
| 04:05   | 24 (0.081)  | 8 (0.027)   | 3.13 (1.33–8.19) | 4.00 × 10^{-3} | 0.060 |
| 07:01   | 25 (0.084)  | 31 (0.105)  | 0.78 (0.43–1.4)  | 0.370 | NA |
| 10:01   | 6 (0.020)   | 13 (0.044)  | 0.44 (0.14–1.28) | 0.096 | NA |
| 11:01   | 1 (0.003)   | 13 (0.044)  | 0.07 (0–0.49)    | 1.0 × 10^{-3} | 0.015 |
| 11:04   | 1 (0.003)   | 10 (0.034)  | 0.1 (0–0.68)     | 6.0 × 10^{-3} | 0.086 |
| 13:02   | 1 (0.003)   | 10 (0.034)  | 0.1 (0–0.68)     | 6.0 × 10^{-3} | 0.086 |
| 15:01   | 3 (0.01)    | 12 (0.041)  | 0.24 (0.04–0.9)  | 0.017 | 0.227 |
| 15:02   | 2 (0.007)   | 10 (0.034)  | 0.19 (0.02–0.91) | 0.018 | 0.238 |
| 16:01   | 18 (0.060)  | 16 (0.050)  | 1.12 (0.53–2.39) | 0.754 | NA |
| 16:02   | 7 (0.023)   | 23 (0.078)  | 0.28 (0.1–0.7)   | 2.0 × 10^{-3} | 0.030 |

$^a$Study subjects comprised 149 T1D patients and 147 normoglycemic healthy controls. Significant differences are reported in bold.

$^b$Corrected $P$ value, calculated as $P \times n$, where $n$ = number of comparisons.

$^c$Number (frequency).
of DRB1*16:02-DQB1*05:02 haplotype [0.024 vs. 0.075, OR (95% CI) = 0.30 (0.11–0.74), P = 0.041] were seen in T1D patients compared to controls. This assigned T1D susceptibility and protective nature to these haplotypes, respectively (Table 4).

**Distribution of DRB1-DQB1 Diplotypes**

Parallel to the differential distribution of 2-locus haplotypes among T1D patients and controls, distinct DRB1–DQB1 + DRB1–DQB1 diplotypes were seen in T1D patients. Extensive diversity in the diplotypes identified was seen, and as such we focused on the DRB1*03- and DRB1*04-containing diplotypes for analysis. As shown in Table 5, DRB1*03:01–DQB1*02:01 + DRB1*04:02:05–DQB1*03:02 0.104 vs. 0.006, OR = 25.03 (8.23–97.20, p = 2.6 × 10^-10) followed by the homozygous DRB1*03:01–DQB1*02:01 + DRB1*03:01–DQB1*02:01 [0.094 vs. 0.01, OR = 8.72 (3.17–25.32), p = 3.18 × 10^-5] were associated with heightened risk for T1D.

**Linkage Disequilibrium Between DRB1 and DQB1 Loci**

D' and W_a values, as well as W_{DRB1/DQB1} and W_{DQB1/DRB1} measures, which assess the global linkage disequilibrium (LD) between DRB1 and DQB1 loci in T1D patients and control groups are shown in Supplementary Table S5. There were no substantial differences between T1D cases and controls in terms of LD. Strong LD between DRB1 and DQB1 loci is illustrated by the high D' measure (0.92 in patients and 0.95 in controls), and to a lesser extent by W_a (0.75 in patients and 0.72 in controls). The ALD measures (W_{DRB1/DQB1} and W_{DQB1/DRB1}) dissect the variation on each locus conditioned on the other. Comparison of the W_{DRB1/DQB1} (0.89 in patients and 0.90 in controls) with W_{DQB1/DRB1} (0.71 in both groups) indicated less variation among DRB1 alleles related to DQB1, when compared to DQB1 alleles related to DRB1.

**DISCUSSION**

The HLA contribution to T1D genetic susceptibility differs between populations and ethnic groups (Noble et al., 2013), largely due to varied frequencies and functional associations of DRB1 and DQB1 alleles and haplotypes (susceptible, protective). Key DRB1 and DQB1 alleles and haplotypes associated with T1D were reported for Caucasian and non-Caucasian populations (Petrone et al., 2001; Erlich et al., 2008; Ilonen et al., 2009; Noble et al., 2013), which included DRB1*03:01, DRB1*04:02, DRB1*04:05, DQB1*02:01, and DQB1*03:02 along with DRB1*03:01–DQB1*02:01 (DR3), DRB1*04:02–DQB1*03:02 (DR4), and DRB1*04:05–DQB1*03:02 haplotypes also observed in this study and studies on other Arab populations from Bahrain, Tunisia, Lebanon and Saudi Arabia (Al-Harbi et al., 2004; Al-Jenaidi et al., 2005; Stayouss et al., 2009; Manan et al., 2010; El-Amir et al., 2015; Eltayeb-Elsheikh et al., 2020). It is noteworthy that no DR3 or DR4 haplotype linked with T1D.
was detected in East and Southeast Asians (Hashimoto et al., 1994; Kawabata et al., 2002).

**DRB1*04:01~DQB1*03:02** (0.34% controls frequency) and **DRB1*04:01~DQB1*03:01** (not seen in controls) were rare in Emiratis. This was reminiscent of findings in Europeans where **DRB1*04:01~DQB1*03:02** haplotype the second susceptibility haplotype, compared to **DRB1*04:01~DQB1*03:01** which was protective in Europeans (Erlich et al., 2008; Noble et al., 2013), but not Africans (Onengut-Gumuscu et al., 2019). In our study, the **DRB1*04:01~DQB1*03:02** haplotype were more prevalent in the healthy controls but were not statistically different after correcting for multiple comparisons. The highest T1D risk in Emiratis was conferred by **DRB1*04:05~DQB1*03:02**, **DRB1*04:02~DQB1*03:02** and **DRB1*03:01~DQB1*02:01** haplotypes. By comparison, the highest risk in European was imparted by **DRB1*04:05~DQB1*03:02**, **DRB1*04:01~DQB1*03:02**, **DRB1*04:02~DQB1*03:02**, and **DRB1*03:01~DQB1*02:01** (Erlich et al., 2008).

**DQB1*03:03**, **DRB1*08:01**, **DRB1*08:02**, and **DRB1*09:01** were rare among patients or controls in the present study. Moreover, **DRB1*03:02** was rare in the Emirati study population (Al-Yafei et al., 2019; Arnaiz-Villena et al., 2019) and European derived populations; and frequent in **DQB1*04:02-containing haplotypes in Africans, protecting against T1D (Howson et al., 2013). **DQB1*04:01**, common in East Asians (Kawabata et al., 2002), is rare in Emiratis (Al-Yafei et al., 2019; Arnaiz-Villena et al., 2019). Furthermore, several **DRB1~DQB1** haplotypes associated with T1D in Europeans, Asians, and Africans were not observed here. For example, the **DRB1*04:05~DQB1*02:01** haplotype predisposed to T1D susceptibility in African Americans, while the African **DR3** (**DRB1*03:02~DQB1*04:02**) haplotype was protective (Noble et al., 2013). In addition to **DR3** (**DRB1*03:01~DQB1*02:01**) and **DR4** (**DRB1*04~DQB1*03:02**, **DRB1*08:01~DQB1*04:02**) is a T1D predisposing haplotype in Europeans (Thomson et al., 2007). The African **DRB1*03:02~DQB1*04:02** and **DRB1*04:05~DQB1*02:01** haplotypes were rare in our study and in European populations. The **DQB1*04:02** allele was more prevalent in the Emirati healthy controls but was not statistically different after correcting for multiple comparisons. **DRB1*08:02~DQB1*03:02**, **DRB1*09:01~DQB1*03:03**, and **DRB1*04:05~DQB1*04:01** haplotypes, associated with increased T1D susceptibility in East Asians (Ikegami et al., 2008; Katahira et al., 2009), were rare in the current study population (Supplementary Tables S2, S4). The **DRB1*04:05~DQB1*04:01** haplotype common in East Asia populations (Japanese, Taiwanese, Filipinos), is rare in Europeans and African Americans (Thomson et al., 2007), in line with the findings here. On the other hand, **DRB1*09:01~DQB1*03:03**, also rare in African Americans, is found in Europeans and East Asians (Thomson et al., 2007). It should be noted that a unique (DR9) **DRB1*09:01~DQA1*03:01~DQB1*02:02** haplotype (but not the **DRB1*09:01~DQB1*03:03**) haplotype has been detected in Africans (Noble et al., 2013).

While high prevalence of **DRB1*07:01~DQB1*02:02** was seen in controls (9.18%) and cases (7.05%), no significant difference in its distribution between cases and controls was seen. **DRB1*07:01~DQA1*02:01~DQB1*02:02** conferred some protection against T1D in Europeans (Erlich et al., 2008), while **DRB1*07:01~DQA1*03:01~DQB1*02:02** was susceptible for T1D in Africans (Noble et al., 2013). Varied T1D risk of **DR7-containing haplotypes was dependent on the DQA1 allele contained in the DRB1*07:01~DQA1*03:01~DQB1*02:02** haplotype. Noble et al. (2013) showed that the **DRB1*07:01~DQB1*03:03** haplotype was protective of T1D in Europeans but was rare in Africans; this haplotype is rare in the current study (0.34% in both groups). Moreover, the distribution of **DRB1*01:01~DQB1*05:01**, **DRB1*01:02~DQB1*05:02**, **DRB1*16:01~DQB1*05:02**, and **DRB1*10:01~DQB1*05:01** haplotypes were comparable between T1D cases and controls. While **DRB1*01:01~DQB1*05:01** was shown earlier to be associated with increased susceptibility to T1D (Thomson et al., 2007), this was not consistent with subsequent studies (Erlich et al., 2008). The **DRB1*16:02~DQB1*05:02** haplotype was protective for T1D while **DRB1*11:01~DQB1*03:01** and **DRB1*10:01~DQB1*05:01** were more prevalent in the healthy controls but were not statistically different after correcting for multiple comparisons. **DRB1*15:01~DQB1*06:02**, **DRB1*14:01~DQB1*05:03**, and **DRB1*07:01~DQB1*03:03** (Noble et al., 1996; Petrone et al., 2001; Noble et al., 2011) are protective in Europeans but were observed at low frequencies in the present study and were binned (Supplemental S2 and S4). **DRB1*15:01~DQB1*06:02** was seen in approximately 20% of Europeans, but in only 1% of T1D individuals (Noble et al., 1996). **DRB1*16:02~DQB1*05:02** is common in controls (7.48%) and patients (2.35%), but is rare in Europeans, Africans, and Asians (Hashimoto et al., 1994). **DRB1*16:01~DQB1*05:02**, a common DR2 haplotype in the studied population (6.04 and 5.44% in patients and controls, respectively), was not associated with T1D. In addition, **DRB1*15:01~DQB1*06:02**, a T1D protective haplotype in most ethnicities (Osoegawa et al., 2019), was detected at low frequency in patients (0.67%) and controls (1.67%). Moreover, the (protective) **DRB1*15:03~DQB1*06:02**, **DRB1*08:04~DQB1*03:01**, and **DRB1*03:02~DQB1*04:02** African haplotypes were rare in our study population.

Differential contribution of **DR~DQ** haplotypes to T1D risk were recognized; this was dictated by the specific ethnic background. Most of our T1D patients carried (**DRB1*03:01~DQB1*02:01**) (**DR3**) or (**DRB1*04:02~DQB1*03:02**) (**DR4**) haplotypes (87%), and 23% of these were carriers of the heterozygous **DR3/DR4** diplotype. In particular, the **DRB1*03:01~DQB1*02:01** diplotype imparted the highest T1D risk, followed by **DRB1*03:01~DQB1*02:01** (**homozygous** **DRB1*03:01~DQB1*02:01** diplotype). This was comparable to Europeans, where most (90%) T1D patients were **DR3** or **DR4** carriers, with 40% carrying the **DR3/DR4** diplotype (Ronningen et al., 1991; Noble et al., 1996), which is higher than the 12% **DR3/DR4** diplotype carrier rate seen in Africans (Noble et al., 1996). Furthermore, the highest risk for T1D in Europeans was conferred by the **DR3/DR4** diplotype, rather than **DR3/DR3** (Noble et al., 1996; Hermann et al., 2003; Erlich et al., 2008), while in East Asians, the highest T1D risk was conferred by the **DR4/DR9** diplotype (Ikegami et al., 2008). This absence of
DR3 might explain the low prevalence of T1D in these populations, as suggested earlier (Ikegami et al., 2008).

The apparent discrepancies between our results and those of other populations can be attributed to several factors, including race/ethnicity, incidence of T1D, sample size, genotyping methods, and other factors (Park, 2007; Polychronakos and Li, 2011). This was highlighted by the HLA allele/haplotype frequencies between our population and Europeans, Africans, and East Asians (Al-Yafei et al., 2019; Arnaiz-Villena et al., 2019). This in turn explains, at least in part, the variations in T1D prevalence and incidence (Patterson et al., 2012). The high LD values between DRB1 and DQB1 loci were found in Emiratis, consistent with the findings in other ethnic groups. LD values were similar in cases and controls, and were identical for W\textsubscript{DQB1/DRB1}, suggesting equivalent diversity of DQB1 alleles within DRB1–DQB1 haplotypes between the groups. The intermediate \( W_n \) LD measure value relative to \( W_{\text{DRB1/DQB1}} \) and \( W_{\text{DQB1/DRB1}} \) measures in patients illustrates the importance for applying the ALD measures for highly polymorphic genetic systems.

CONCLUSION

The highest T1D risk was imparted by the DRB1*03:01–DQB1*02:01/DRB1*04:02–DQB1*03:02 diplotype followed by the DRB1*03:01–DQB1*02:01/DRB1*03:01–DQB1*02:01 diplotype. Emiratis showed similarities with and differences from European, Asian, and African populations in terms of HLA-DRB1 and -DQB1 alleles and haplotypes and their associations with T1D. However, our study had some shortcomings, namely the relatively small sample size, and lack of DQA1 genotyping (especially for DR7+ samples). An interesting dimension of ethnic diversity and possible diverse relationships is highlighted between HLA-DRB1 and -DQB1 genes and T1D across different populations.

DATA AVAILABILITY STATEMENT

All sequences were submitted to the Short Read Archive (SRA) at GenBank and assigned BioSample accession numbers between SAMN26674334 and SAMN26674604 under BioProject PRJNA609073.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by Institutional Review Boards at SKMC (REC-25-10-2016 RS-445) and United Arab Emirates University (AAMDHREC 2016-4255 16-002). Written informed consent to participate in this study was provided by the participants’ legal guardian/next of kin.

AUTHOR CONTRIBUTIONS

ZA, GE, JA and BRA draft the idea of the research and the research proposal. MA and CS conducted the laboratory and genetic analysis. RM and AN did data cleaning. SM, WO and WA conducted the data analysis, prepared the tables and contributed to the writing of the statistical components of the study. ZA wrote the first draft of the manuscript under supervision of GE. BA, SB, SA, JA, RM and AN contributed to participant’s recruitment and reviewed the manuscript. RM, AN and WO prepare the manuscript for publication. All authors reviewed the final version of the manuscript and gave approval for submission for publication of this manuscript.

FUNDING

This work was funded by the College of Medicine and Health Sciences; United Arab Emirates University grant code 21M1034-4 IRCA. This work was also supported by National Institutes of Health (NIH) National Institute of Allergy and Infectious Disease (NIAID) grant R01AI28775 (SM). The content is solely the responsibility of the authors and does not necessarily reflect the official views of the NIAID, NIH or United States Government.

ACKNOWLEDGMENTS

The authors are most grateful to all the patients and parents/guardians who for participation to the study, all physicians, diabetes educators and nurses who helped identification of appropriate patients, and admin and technical staff for data entry and support.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fgene.2022.841879/full#supplementary-material

REFERENCES

Ahmadov, G. A., Govender, D., Atkinson, M. A., Sultanova, R. A., Eubova, A. A., Wasserfall, C. H., et al. (2018). Epidemiology of Childhood-Onset Type 1 Diabetes in Azerbaijan: Incidence, Clinical Features, Biochemistry, and HLA-DRB1 Status. *Diabetes Res. Clin. Pract.* 144, 252–259. doi:10.1016/j.diabres.2018.09.009

Al-Yafei, Z., Goeury, T., Alvares, M., Al Seiari, M., Sanchez-Mazas, A., and Elghazali, G. (2020). United Arab Emirates: Unusual Departure from Neutrality towards Excess of Homozygotes at the HLA-B Locus. *HLA* 95 (5), 470–473. doi:10.1111/tan.13774

Al-Harbi, E. M., Abbassi, A.-J., Tamim, H., al-Jenaidi, F., Koohi, M., Kamal, M., et al. (2004). Specific HLA-DRB and -DQB Alleles and Haplotypes Confer Disease Susceptibility or Resistance in Bahraini Type 1 Diabetes Patients. *Clin. Vaccine. Immunol.* 11 (2), 292–296. doi:10.1128/cvi.11.2.292-296.2004
Al-Jenhaidi, F. A., Wakim-Ghorayeb, S. F., Al-Abassi, A., Arekat, M. R., Irani-Hakime, N., Najm, P., et al. (2005). Contribution of Selective HLA-Drb1/dqb1 Alleles and Haplotypes to the Genetic Susceptibility of Type 1 Diabetes Among Lebanese and Bahraini Arabs. J. Clin. Endocrinol. Metab. 90 (9), S104–S109. doi:10.1210/jc.2005-1166

Arnaiz-Villena, A., Yafei, Z. A., Juarez, I., Palacio-Gruber, J., Mahri, A. A., Al-Abbasi, A., Arekat, M. R., Irani-Hakime, N., Najm, P., et al. (2019). Genetic Study from United Arab Emirates (UAE), Abu Dhabi. Hum. Immunol. 80 (7), 421–422. doi:10.1016/j.humimm.2019.04.013

Bergholdt, R., Brorsson, C., Palleja, A., Berchtold, L. A., Fawwad, A., Basit, A., Lane, J. A., Mack, S. J., et al. (2016). Keptin2 Enhances β-cell Function and Inhibits β-cell Death. Cell 164 (1), 1–17. doi:10.1016/j.cell.2015.12.034

Blanter, M., Sork, H., Tuomela, S., and Flodström-Tullberg, M. (2019). Genetic and Environmental Interaction in Type 1 Diabetes: a Relationship between Genetic Risk Alleles and Molecular Traits of Enterovirus Infection. Curr. Diab Rep. 19 (9), 82. doi:10.1007/s11892-019-1192-8

Dem丕st, A. P., Laird, N. M., and Rubín, J. B. (1977). Maximum Likelihood from Incomplete Data via the EM Algorithm. J. R. Stat. Soc. Ser. B (Methodological) 39 (1), 1–22. doi:10.1111/j.2517-8616.1977.tb01600.x

Eisenbarth, G. S. (2010). Banting Lecture 2009: an Unfinished Journey: Molecular Pathogenesis to Prevention of Type 1A Diabetes. Diabetes 59 (4), 759–774. doi:10.23736/S0012-7240.10-1855-5

El-Amir, M. I., El-Feky, M. A., Laine, A. P., Härkönen, T., El-Badawy, O., Eltayeb, A. A., et al. (2015). Protective HLA-DRB1*03 Haplotype. J. Clin. Endocrinol. Metab. 90 (8), 463–469. doi:10.1210/jc.2015-2572

Fawwad, A., Govender, D., Ahmedani, M. Y., Basit, A., Lane, J. A., Mack, S. J., et al. (2019). Clinical Features, Biochemistry and HLA-DRB1 Status in Youth-Onset Type 1 Diabetes in Pakistan. Diabetes Res. Clin. Pract. 149, 9–17. doi:10.1016/j.diabres.2019.01.023

Gong, C., Meng, X., Jiang, Y., Wang, X., Cui, H., Chen, X., et al. (2015). Trends in Childhood Type 1 Diabetes Mellitus Incidence in Beijing from 1995 to 2010: A Retrospective Multicenter Study Based on Hospitalization Numbers of Children with Type 1 Diabetes. Diabetologia 58 (6), 1394–1402. doi:10.1007/s00125-015-3724-x

Guo, S. W., and Thompson, E. A. (1992). Performing the Exact Test of Hardy-Weinberg Proportion for Multiple Alleles. Biometrics 48 (2), 361–372. doi:10.2307/2532296

Hashimoto, M., Kinoshita, T., Yamazaki, M., Tanaka, H., Imanishi, T., Ibara, H., et al. (1994). Gene Frequencies and Haplotypic Associations within the HLA Region in 916 Unrelated Japanese Individuals. Tissue Antigens 44 (3), 166–173. doi:10.1111/j.1399-0399.1994.tb03275.x

Hemm, R., Tuirpimne, H., Laine, A. P., Veijola, R., Knip, M., Simell, O., et al. (2003). HLA DR-DQ-Encoded Genetic Determinants of Childhood-Onset Type 1 Diabetes in Finland: An Analysis of 622 Nuclear Families. Tissue Antigens 62 (2), 162–169. doi:10.1038/sj.taN.6000731

Howson, J. M. M., Roy, M. S., Zeitzels, L., Stevens, H., and Todd, J. A. (2013). HLA Class II Gene Associations in African American Type 1 Diabetes Reveal a Protective HLA-DRB1*03 Haploype. Diabet. Med. 30 (6), 710–716. doi:10.1111/dme.12148

Ikemani, H., Nose, S., Babaya, N., Hiromine, Y., and Kawahata, Y. (2008). Genetic Basis of Type 1 Diabetes: Similarities and Differences between East and West. Rev. Diabet. Stud. 5 (2), 64–72. doi:10.1900/RDS.2008.5.64

Ilonen, J., Kocova, M., Lipponen, K., Sukarova-Angelovska, E., Jovanovska, A., and Knip, M. (2009). HLA-DR-DQ Haplotypes and Type 1 Diabetes in Macedonia. Hum. Immunol. 70 (6), 461–463. doi:10.1016/j.humimm.2009.03.014

International Diabetes Federation (2019). IDF Diabetes Atlas. 9th ed. Brussels: International Diabetes Federation.
Mellitus. Tissue Antigens 37 (3), 105–111. doi:10.1111/j.1399-0039.1991.tb01854.x
Shaltout, A. A., Wake, D., Thanaraj, T. A., Omar, D. M., Al-AbdulRazzaq, D., Channanath, A., et al. (2017). Incidence of Type 1 Diabetes Has Doubled in Kuwaiti Children 0–14 Years over the Last 20 Years. Pediatr. Diabetes 18 (8), 761–766. doi:10.1111/pedi.12480
Single, R. M., Strayer, N., Thomson, G., Paunic, V., Albrecht, M., and Maiers, M. (2016). Asymmetric Linkage Disequilibrium: Tools for Assessing Multiallelic LD. Hum. Immunol. 77 (3), 288–294. doi:10.1016/j.humimm.2015.09.001
Stayoussef, M., Benmansour, J., Al-Jenaidi, F. A., Nemr, R., Ali, M. E., Mahjoub, T., et al. (2009). Influence of Common and Specific HLA-Drb1/dqb1 Haplotypes on Genetic Susceptibilities of Three Distinct Arab Populations to Type 1 Diabetes. Clin. Vaccin. Immunol. 16 (1), 136–138. doi:10.1128/CVI.00215-08
Thomson, G., and Single, R. M. (2014). Conditional Asymmetric Linkage Disequilibrium (ALD): Extending the Biallelic R² Measure. Genetics 198 (1), 321–331. doi:10.1534/genetics.114.165266
Thomson, G., Valdes, A. M., Noble, J. A., Kockum, I., Grote, M. N., Najman, J., et al. (2007). Relative Predispositional Effects of HLA Class II DRB1-DQB1 Haplotypes and Genotypes on Type 1 Diabetes: a Meta-Analysis. Tissue Antigens 70 (2), 110–127. doi:10.1111/j.1399-0039.2007.00867.x
Todd, J. A., Walker, N. M., Walker, N. M., Cooper, J. D., Smyth, D. J., Downes, K., et al. (2007). Robust Associations of Four New Chromosome Regions from Genome-wide Analyses of Type 1 Diabetes. Nat. Genet. 39 (7), 857–864. doi:10.1038/ng2068
World Health Organisation (1985). Diabetes Mellitus: Report of a WHO Study Group. Technical Report Series No. 727. Geneva: WHO.
Xia, Y., Xie, Z., Huang, G., and Zhou, Z. (2019). Incidence and Trend of Type 1 Diabetes and the Underlying Environmental Determinants. Diabetes Metab. Res. Rev. 35 (1), e3075. doi:10.1002/dmrr.3075
Zabeen, B., Govender, D., Hassan, Z., Noble, J. A., Lane, J. A., Mack, S. J., et al. (2019). Clinical Features, Biochemistry and HLA-DRB1 Status in Children and Adolescents with Diabetes in Dhaka, Bangladesh. Diabetes Res. Clin. Pract. 158, 107894. doi:10.1016/j.diabres.2019.107894
Zayed, H. (2016). Genetic Epidemiology of Type 1 Diabetes in the 22 Arab Countries. Curr. Diab Rep. 16 (5), 37. doi:10.1007/s11892-016-0736-4

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors, and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Al Yafei, Mack, Alvares, Ali, Afandi, Beshyah, Sharma, Osman, Mirgiani, Nair, Al Remithi, Al Jubeh, Almawi, ALKaabi and ELGhazali. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.